Published by Josh White on 19th January 2023
(Sharecast News) - C4X Discovery updated on its 'MALT-1' inhibitor programme on Thursday, explaining that the overexpression or over-activation of MALT-1 has been observed in a range of lymphomas and leukemias such as MALT lymphoma, diffuse large B-cell lymphoma and chronic lymphocytic leukaemia.